KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Operating Leases (2019 - 2025)

Pacific Biosciences Of California has reported Operating Leases over the past 7 years, most recently at $57.0 million for Q4 2025.

  • Quarterly results put Operating Leases at $57.0 million for Q4 2025, up 282.46% from a year ago — trailing twelve months through Dec 2025 was $57.0 million (up 282.46% YoY), and the annual figure for FY2025 was $57.0 million, up 282.46%.
  • Operating Leases for Q4 2025 was $57.0 million at Pacific Biosciences Of California, up from $54.3 million in the prior quarter.
  • Over the last five years, Operating Leases for PACB hit a ceiling of $57.0 million in Q4 2025 and a floor of $14.9 million in Q4 2024.
  • Median Operating Leases over the past 5 years was $36.6 million (2023), compared with a mean of $37.0 million.
  • Biggest five-year swings in Operating Leases: crashed 53.34% in 2021 and later soared 282.46% in 2025.
  • Pacific Biosciences Of California's Operating Leases stood at $50.0 million in 2021, then decreased by 17.81% to $41.1 million in 2022, then fell by 23.04% to $31.6 million in 2023, then plummeted by 52.81% to $14.9 million in 2024, then soared by 282.46% to $57.0 million in 2025.
  • The last three reported values for Operating Leases were $57.0 million (Q4 2025), $54.3 million (Q3 2025), and $52.9 million (Q1 2025) per Business Quant data.